OBJECTIVE: False-negative (FN) uptake of 18F-fluorodeoxyglucose (FDG) can be divided into those cases related to technological limitations of positron emission tomography (PET) and those related to inherent properties of neoplasms. Our goal was to clarify possible factors causing FN PET results in patients with solid-type pulmonary adenocarcinomas (PAs).
INTRODUCTION
The use of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has become widely accepted in the current management of lung cancer [1] . This tool is not only useful for staging, evaluating therapeutic effects, and for observation, but also for differentiating localized malignant pulmonary lesions from non-malignant ones [2] .
Almost all current guidelines recommend the routine use of 18F-FDG-PET to characterize any pulmonary lesion suspected of being malignant [3] ; however, several authors have nonetheless recently reported a remarkable rate of false-negative (FN) results when PET is used with primary lung cancers [4] [5] [6] [7] [8] [9] .
A body of evidence supports the idea that several factors could affect the maximum standardized uptake values (SUVmax) in PET images. The factors reported as those most significantly impacting the homogeneity of the SUVmax values include blood glucose concentration, body weight, lesion size, lesion location, and histological type [9] [10] [11] . It has been shown that pulmonary lesions (suspected to be malignant) appearing as ground-glass opacities (GGOs) on thin-section computed tomographic (CT) images are more likely to have negative findings on PET scans [12, 13] . Indeed, the third edition of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [3] does not recommend that the PET/CT scan be used in the preoperative work-up examination of GGOs because of its very low sensitivity in such cases. Similarly, in the recent literature [14, 15] , emerging evidence indicates that bronchopulmonary carcinoid tumours often present with very low or no uptake of FDG (especially in those forms that are typical), which results in a very low sensitivity of the 18F-FDG-PET scan in such tumours.
Even excluding these two categories (predominant GGO-type cancers and bronchopulmonary carcinoid tumours), FN PET findings may occur with a significant frequency with non-small-cell lung cancers (NSCLCs), especially pulmonary adenocarcinomas (PAs). However, to the best of our knowledge, few data have been published regarding the clinical significance of FN PET results for solid-type lung cancers. In addition, no studies have investigated PAs only to determine the possible factors leading to FN PET results. The goal of this study, via a comprehensive retrospective analysis, is to compare the clinical and pathological features of early-stage solid-type PAs in order to identify which factors are associated with (18F-FDG) PET-induced FN results.
PATIENTS AND METHODS
From January 2007 to December 2014, we retrospectively reviewed the clinical data, the preoperative thin-section CT images, the 18F-FDG-PET/CT records, and the pathological features of 255 patients with p-stage-1 NSCLC who had undergone surgical resection at our institution. Inclusion criteria were (i) pathological diagnosis of PA, (ii) 18F-FDG-PET/CT scan performed during the preoperative work-up examination (<60 days before surgery), and (iii) solid-type tumour (or lesion with consolidation-totumour ratio (C/T ratio) > _0.5 on the preoperative thin-section CT scan, in accordance with the Japan Clinical Oncology Group 0201 experience [16] ). Exclusion criteria were (i) pathological diagnosis of primary lung cancer different from PA, (ii) 18F-FDG-PET/CT scan not performed or performed more than 60 days before surgery, (iii) predominantly non-solid type PA (lesion with C/ T ratio <0.5 at thin-section CT scan, in accordance with [16] ), and (iv) doubtful diagnosis of primary PA in those cases with a previous history of adenocarcinoma tumours elsewhere in the body.
A total of 94 consecutive solid-type p-stage-1 PAs met the inclusion criteria ( Fig. 1 ) and formed the basis for the focus of our retrospective analysis. Before undertaking our data analysis, we obtained institutional review board approval (protocol number 2016/0006352) to use the retrospectively collected data stemming from standard clinical practice for research purposes. Data related to gender, age, body weight and blood glucose level detected at the moment of PET/CT scan evaluation and to tumour size, tumour location and pathological features were systematically reviewed and recorded (Table 1) .
Thin-section CT examination
High-resolution CT scans of the chest were performed using a 16-slice multidetector CT scanner. The images acquired were spaced from the apex to the base of the lung (1.25-mm collimation at 10-mm intervals). The thin-section CT images were displayed with lung (level, -600 HU; width, 1700 HU) and mediastinal (level, 30 HU; width, 400 HU) window settings in a multiplanar format. The CT images were assessed retrospectively for nodule size and appearance. To determine the size of the nodule, the largest diameter of the tumour on the window image of the transverse lung was measured where the dimensions of the nodule were largest. Like Cho et al. [17] , we investigated the C/T ratio, defined as the proportion of the maximum consolidation (C) diameter divided by the maximum tumour (T) diameter. The maximum tumour diameter, the consolidation diameter, and the presence and extent of consolidation or GGO components in the tumour were determined digitally on the basis of the findings from the lung window on the CT scan. The consolidation component was defined as an area of increased opacification that completely obscured the underlying vascular markings. The GGO was defined as an area of slight homogeneous increase in density that did not obscure the underlying vascular markings. These radiological criteria were adopted, taking into account that noninvasive PAs (usually negative on the PET/CT scan [12] ) are mainly represented by a C/T ratio <0.5. Therefore, we divided our cohort of patients into two groups based on the consolidation-totumour ratio (C/T ratio = 0.5). In the case of pulmonary nodules that presented with a C/T ratio >0.5, the tumour sizes were calculated taking into account the solid component only, as widely accepted [18] . Finally, the tumour localization was reviewed and the pulmonary lesions assigned to 'upper zone' (all segments of left/right upper lobe, middle lobe, and S6) or 'lower zone' (all segments of left/right lower lobes apart from S6) in accordance with [19] .
PET/CT protocol and imaging analysis
The PET/CT was performed on a dedicated hybrid scanner (Discovery STE; GE Healthcare, Milwaukee, WI, USA). The PET emission images were recorded from the head to the groin (seven or eight bed positions). The CT attenuation correction acquisition parameters were 120 kV voltage, 80 mA tube current, and 3.75-mm slice thickness. Details of preparation of patients for the PET/CT examination and image acquisition were reported previously [20] . At the time of the injection of the tracer, all patients had a blood glucose level <150 mg/dl. The PET/CT findings were independently reviewed by two experienced nuclear medicine physicians (A.F. and M.R.) who reread all the reports blinded to the original ones and reached a consensus in all cases. Any focal accumulation of tracer outside the normal distribution area or higher than the surrounding physiological uptake area was considered an abnormal finding. The SUV was normalized by body weight, and the SUVmax was calculated as the highest tumour voxel value for the primary lung tumour in each patient. As widely accepted [2] , we adopted the SUVmax cut-off value of 2.5 when discriminating a positive from a negative result on an 18F-FDG-PET/CT scan.
Surgical policy, pathological diagnosis, and histological classification
The surgical policy adopted when planning the pulmonary resection extension was based on the following assumptions: (i) to a lesser extent than a lobectomy, parenchymal resection was considered oncologically inappropriate and was never performed in 'clinically fit' patients; (ii) sub-lobar resection (segmentectomy or wedge resection) was indicated only in patients judged 'clinically unfit' for lobar resection; and (iii) lymph node dissection (lobespecific or complete) was performed in all cases, and the mediastinal tissue encompassing the lymph nodes was dissected and removed systematically within typical anatomical landmarks.
The surgical-pathological stage was assigned according to the seventh TNM classification system as defined by the International Staging System for Lung Cancer; staging data from patients observed and treated in clinical practice before its introduction were updated appropriately so that we had homogeneous staging information for all patients in the cohort. The lung specimens were reviewed independently by two lung pathologists (A.C. and S.B.) to determine the adenocarcinoma subtype according to the criteria of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) [21] . The pathologists had no information about the 18F-FDG-PET/CT results. When the pathologists did not agree on the pathological diagnoses of a case, they initiated a dialogue while viewing specimens under a double-headed microscope. Consensus was achieved in all cases.
End-points
The end-points of our study were (i) to compare the PET findings of early-stage PAs with their clinical and pathological features using multivariable analysis and (ii) to investigate the possible correlation between the recent pathological reclassification of IALSC/ERS/ATS and PET findings.
Statistical analysis
Descriptive statistics were performed to investigate the sample characteristics: mean, median class interval, interquartile range (IQR), and standard deviation were chosen to summarize continuous variables, whereas absolute and relative frequencies (n, %) were used for categorical variables. The assumption of normality for continuous variables was verified statistically using the Kolmogorov-Smirnov test. The groups were compared using the Student's t-test for continuous variables and Pearson's chi-square test or the Fisher's exact test for categorical variables. The MannWhitney U-test was used for between-group comparisons for not normally distributed variables. Multivariable logistic analysis was used to identify the independent predictors of PET positive or negative results using the five factors noted above. The threshold for statistical significance was set at P < 0.05. IBM SPSS Statistics 23 for Windows (SPSS, Chicago, IL, USA) was used for statistical analyses. 
RESULTS
Demographics and clinicopathological features are summarized in Table 1 . There were 58 men and 36 women (mean age= 68.7 ± 8.9 years, range 42-85). The median tumour size was 2.1 cm (IQR 1.5-3.0 cm) with half of the cases (45.7%) measuring <2 cm. According to the standard cut-off value (SUVmax = 2.5), 77 lesions (81.9%) were judged as PET-positive and 17 (18.1%), as PET-negative (Fig.  2) . Overall, the median SUVmax was 5.7 (IQR: 2.8-10.3) as shown graphically in Fig. 3A; higher SUVmax values (P < 0.001) were observed (Fig. 3B ) in PAs with a maximum diameter >2 cm (median SUVmax = 9.0; IQR 4.6-14.6) when compared with SUVmax values of PAs measuring <2 cm (median SUVmax= 4.1; IQR 2.2-5.9). We observed a large variability in the histological IASLC/ERS/ ATS patterns of FDG uptake (Fig. 4A) . The lepidic, mucinous and colloid patterns were associated with the lowest mean SUVmax values (3.6, 4.4, and 2.2, respectively), whereas the acinar, micropapillary, solid and papillary patterns were associated with the highest mean SUVmax values (11.4, 7.5, 11.1, and 7.9, respectively). When we clustered the cohort in two histological classes (class A, colloid/mucinous/lepidic and class B, micropapillary/ solid/acinar/papillary) on the basis of previous data reported in the literature [22] [23] [24] , we found a significant difference in the metabolic uptake patterns (median SUVmax = 2.8, IQR 1.7-4.9 in class A vs median = 7.4 IQR 4.5-13.9 in class B, P < 0.001) (Fig. 4B) .
The distribution of PET FN cases according to the variables analysed and the results of the univariable analysis are shown in Table 2 . The IASLC/ATS/ERS aggregated clusters (class A versus class B) and, to a lesser extent, tumour location and tumour size were relevant factors for determining whether PET results were negative or positive. In particular, remarkable PET FN rates were noted in histological class A (37.5%), in PAs located in the lower zone (31.0%) and in lesions measuring <2 cm (27.9%). On multivariable regression analysis (Table 2) , only the histological IASLC/ ATS/ERS classification proved to have a statistically significant impact, with mucinous/lepidic/colloid PAs presenting a 7-fold risk of a FN result compared with other histological subtypes (OR:7.23, 95% CI: 2.05-25.43, P = 0.002).
DISCUSSION
The results seen on the PET/CT scans obtained during the workup examination of a pulmonary lesion would affect the surgeon's decision to either obtain a tissue diagnosis surgically or follow up with serial imaging of the lesion. Thus, clinicians prescribing an FDG-PET/CT examination to diagnose a pulmonary lesion must consider how the result of the examination would influence their decision making [25] .
A meta-analysis of the diagnostic accuracy of FDG-PET demonstrated very high sensitivity and specificity rates [26] , but the tests were performed in select centres, thereby introducing potential biases. Indeed, Grogan et al. [27] recently showed that, in a national surgical population with clinical stage-1 NSCLC, diagnostic FDG-PET performed poorly compared with results in published studies; they concluded that, in daily clinical practice, a positive result from a PET scan is not definitive proof of malignancy for an undefined lung nodule.
In this study, we retrospectively analysed the 18F-FDG-PET findings from 94 cases of 'solid-type' p-stage-1 surgically treated PA and observed a remarkable number of cases with mild to very low uptake of the tracer (around 18% of lesions with SUVmax <2.5). As remarked previously, despite the fact that several studies and a meta-analysis [23] have shown that FDG-PET has a high sensitivity for malignant lung tumours [9] , in current clinical practice, FN results from 18F-FDG-PET scans are far too common. Iwano et al. [9] compared PET scan findings to the clinical and pathological features of a cohort of 187 solid-type primary lung cancers. A total of 44 lesions (21.4%) were judged to be PET negative (cutoff of SUVmax: 2.5), and the logistic analysis revealed that lesion size and histological tumour type were significant factors in determining whether the PET findings were negative. The authors concluded their analysis by suggesting that pulmonary lesions < _2 cm and a pathological analysis consistent with bronchioloalveolar carcinoma and well-differentiated adenocarcinoma have a tendency for negative PET findings. On the other hand, squamous cell carcinoma, adenosquamous carcinoma, and large-cell carcinoma were mostly PET positive. This study identified some factors associated with PET FN results, despite some clear inclusion biases: the inclusion of a histological type well known to present with low avidity to FDG (previously called bronchioloalveolar carcinoma) and the inclusion of different primary lung neoplasms with different stages. Basically, we agreed with this inspiring insight, reproducing the analysis in a more homogeneous and specific cohort consisting of solid-type p-stage-1 PAs only. Therefore, we did not observe any case of adenocarcinoma in situ or minimally invasive adenocarcinoma because these lung lesions usually appear as predominantly GGO (excluded from the present analysis). When correlating the findings from the PET scans with the clinical and pathological features, we observed a significant correlation with tumour size (tumour > 2 cm vs tumour < 2 cm), tumour location (upper zone versus lower zone), and IASLC/ATS/ERS histological pattern. In line with other authors [19] , we observed that PAs located in the lower zones of the lung presented with lower uptake values (SUVmax) when compared with SUVmax values of PAs arising in the upper zones; nevertheless, location was not an independent factor associated with a PET FN result. Kawano et al. [28] reported that the distance of the respiratory motion of a lesion located in the lower lung area (S7-S10 of bilateral lower lobes) was significantly greater than that in the upper lung area and that the SUVmax of a PET scan of a freely breathing patient should not be accepted as accurate for small lesions in the lower lung area. Moreover, Meirelles et al. [29] demonstrated that SUV results linked to thoracic lesions in PET scans taken while the patient was holding his or her breath were 14% greater than SUV results on PET scans from freely breathing patients.
The correlation between findings from PET scans and IASLC/ ATS/ERS histopathological subtypes of lung adenocarcinomas is a topic of interest. Nakamura et al. [27] recently explored the association of SUVmax measured in preoperative FDG-PET/CT and histological (IASLC/ATS/ERS) subtypes of surgically treated PAs (stages 1-3) in a large cohort of cases (n = 255). They showed that the SUVmax values were closely associated with histological subtypes in specimens, distinguishing three different aggregated subgroups that correlated with different radiometabolic patterns and different prognoses. In addition, they reported more than 50% of PAs with SUVmax <1.95, probably due to the fact that, in comparison to the present analysis, they included noninvasive neoplastic forms (adenocarcinoma in situ and minimally invasive adenocarcinoma). In line with these results, Kadota et al. [22] evaluated 222 patients with pathological stage-1 PA and demonstrated a strong correlation between the SUVmax values on FDG-PET scans and the IASLC/ATS/ERS classification. In line with our results (Fig. 3) , they observed the highest SUVmax values in micropapillary-predominant invasive adenocarcinoma, followed by solid-predominant PAs. In the present analysis, we also evaluated the frequency of PET FN cases in accordance with clinicopathological variables (Table 2) . We observed a different distribution of PET FN cases according to tumour size, tumour location, and IASLC/ATS/ERS aggregated clusters. In detail, remarkable PET FN rates were detected in histological class A (38.7%) PAs located in the lower zone (31.0%) and in PAs measuring <2 cm (27.9%). These data fit within and contribute to a lively debate on the usefulness of an SUVmax cut-off value to discriminate malignant from benign pulmonary disease [25] . The higher the SUVmax cut-off value is set, the lower is the rate of PET falsepositive rate (especially in areas with endemic infectious lung diseases [25] ); nevertheless, the high cut-off value was at the expense of the PET FN rate and sensitivity. In particular, when considering PAs only, the SUVmax cut-off value of 2.5 does not appear to be as strong as discussed in the literature and, more generally, the SUV measurements in such cases should be used with caution in this clinical setting. According to our data, the SUVmax values in some PA cases may be under this threshold but almost all cases showed some degree of activity within the tumour. Thus, the integration of radiometabolic findings with the clinical and radiological characteristics of a pulmonary lesion is of a great importance in planning the most correct diagnostic and therapeutic approaches.
Strengths and limitations
This study has a few limitations and some strengths. First, because it is a retrospective, single-institution study, the PET/CT scanner and scan protocols are almost uniform throughout the cohort. On the other hand, the correlation between PET results and tumour size (P = 0.040) and between PET results and tumour location (P = 0.042) should be interpreted with caution because of the relatively small number of patients enrolled in the study. More generally, an external validation of such results is mandatory before drawing any definitive conclusion.
Secondly, we could not investigate the respiratory motion effect on the SUVmax results using breath-holding or respiratorygated PET [29] . Thirdly, the study group comprised only patients with surgically treated solid-type p-stage-1 PAs (selection bias) and, accordingly, our results may be not translatable to the overall population with suspected malignant pulmonary lesions who underwent preoperative PET/CT scans. On the other hand, this study identified some clinical and histological features of PAs that are independently associated with a PET FN result. These data should suggest a certain caution in the interpretation of PET findings of a pulmonary lesion radiologically suspected of being an adenocarcinoma, especially in small (<2 cm) lesions in the lower zones of the lung.
CONCLUSIONS
The histological IASLC/ATS/ERS pattern significantly influences the uptake of FDG in solid-type p-stage-1 PA. In particular, the fact that colloid/mucinous/lepidic adenocarcinomas have a remarkable tendency to generate FN PET findings warrants attention. 
